honokiol has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M; Mei, M; Tang, L; Xue, N; Zhou, H | 1 |
| Doddapaneni, R; Godugu, C; Singh, M | 1 |
2 other study(ies) available for honokiol and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Honokiol prevents lung metastasis of triple-negative breast cancer by regulating polarization and recruitment of macrophages.
Topics: Animals; Cell Line, Tumor; Humans; Lung Neoplasms; Macrophages; Mice; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2023 |
Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Biphenyl Compounds; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Humans; Lignans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Micelles; Nanoparticles; Particle Size; Structure-Activity Relationship; Surface Properties; Triple Negative Breast Neoplasms | 2017 |